Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy
- 30 March 2002
- Vol. 324 (7340), 757
- https://doi.org/10.1136/bmj.324.7340.757
Abstract
Objective: To assess the evidence for the effectiveness of increasing numbers of drugs in antiretroviral combination therapy. Design: Systematic review, meta-analysis, and meta-regression of fully reported randomised controlled trials. All studies included compared quadruple versus triple therapy, triple versus double therapy, double versus monotherapy, or monotherapy versus placebo or no treatment. Participants: Patients with any stage of HIV infection who had not received antiretroviral therapy. Main outcome measures: Changes in disease progression or death (clinical outcomes); CD4 count and plasma viral load (surrogate markers). Search strategy: Six electronic databases, including Medline, Embase, and the Cochrane Library, searched up to February 2001. Results: 54 randomised controlled trials, most of good quality, with 66 comparison groups were included in the analysis. For both the clinical outcomes and surrogate markers, combinations with up to and including three (triple therapy) were progressively and significantly more effective. The odds ratio for disease progression or death for triple therapy compared with double therapy was 0.6 (95% confidence interval 0.5 to 0.8). Heterogeneity in effect sizes was present in many outcomes but was largely related to the drugs used and trial quality. Conclusions: Evidence from randomised controlled trials supports the use of triple therapy. Research is needed on the effectiveness of quadruple therapies and the relative effectiveness of specific combinations of drugs. What is already known on this topic Triple combination antiretroviral therapy is accepted by clinicians and patients as the usual treatment for HIV and has evolved through an incremental strategy in the numbers of drugs combined Guidance on treatment, however, has predominantly been based on early reports of research There are no published analyses that assess the effectiveness of the increasing numbers of drugs used in combination What this study adds The results of this systematic review support the use of triple therapy but there is inadequate evidence for quadruple or higher combinations Heterogeneity in the effect estimates seems to result from variable effectiveness of different drug combinations, trial duration, and problems with study qualityKeywords
This publication has 94 references indexed in Scilit:
- Initial Therapy with Protease Inhibitor-Sparing Regimens: Evaluation of Nevirapine and DelavirdineClinical Infectious Diseases, 2000
- AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patientsAIDS, 2000
- A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experienceAIDS, 1999
- Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeterAIDS, 1999
- A Randomized Pilot Study of Alternating or Simultaneous Zidovudine and Didanosine Therapy in Patients with Symptomatic Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 1994
- The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.Sexually Transmitted Infections, 1991
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985